A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
Status:
Not yet recruiting
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine overall response rate to combination of S-1 and
Osimertinib in treatment-resistant EGFR mutant lung cancer.